Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 2:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Prandial insulin Clear all
Withdrawn No phase listed Observational

A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes

NCT04667182
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Meal-Tagging App and Web-based Portal:, Fitness Tracker
Other · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
25 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

NCT03169959
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 29, 2026, 2:14 PM EDT
Completed No phase listed Observational

A Study of Technology to Improve Glucose Control in Participants With Type 1 Diabetes

NCT03758430
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Meal-Tagging App, Fitness Tracker
Other · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

NCT04460326
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
Insulin glargine, NovoLog, Insulin Fiasp, Standard carbohydrate diet
Drug · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Not applicable Interventional Results available

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

NCT02846233
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
GLP1 receptor agonist, basal insulin, SGLT2 inhibitor, Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 4 Interventional Results available

Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes

NCT02408120
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Insulin aspart, Supplemental insulin aspart
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

NCT05463744
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes
Interventions
Insulin Efsitora Alfa, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
34
States / cities
Concord, California • Fresno, California • Montclair, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 2 Interventional

A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)

NCT01686620
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
BIOD-123, Lispro (Humalog)
Drug
Lead sponsor
Biodel
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
34
States / cities
Anaheim, California • Chula Vista, California • Concord, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 1 Interventional

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

NCT05184868
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
AT247, NovoLog, Fiasp
Drug
Lead sponsor
Arecor Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 2 Interventional

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

NCT01000922
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Regular Human Insulin, Lispro, VIAject, VIAject 50%, VIAject/Insulin Glargine, Insulin Glargine/VIAject
Drug
Lead sponsor
Biodel
Industry
Eligibility
19 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Not applicable Interventional Results available

Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia

NCT01162499
View directory record Official record
Conditions
Postprandial Hypoglycemia
Interventions
Exendin-(9-39), Vehicle
Drug · Other
Lead sponsor
Diva De Leon
Other
Eligibility
6 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2017 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

A Study of LY900014 in Participants With Type 1 Diabetes

NCT03214367
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
44
States / cities
Mobile, Alabama • Concord, California • Escondido, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

NCT01966978
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes
Interventions
Metformin, Detemir, Liraglutide, Insulin Aspart
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes

NCT00835861
View directory record Official record
Conditions
Non Insulin Dependent Diabetes, Pregnancy
Interventions
Metformin, Insulin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children

NCT00913497
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
insulin glulisine, insulin aspart
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
4 Years to 11 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 4 Interventional Results available

The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients

NCT01810952
View directory record Official record
Conditions
Hyperglycemia, Diabetes Mellitus
Interventions
Glargine insulin, Lispro insulin, NPH Insulin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 29, 2026, 2:14 PM EDT
Terminated Phase 3 Interventional

Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma

NCT00332826
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
Interventions
Technosphere Insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes

NCT03740919
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 17 Years
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

NCT00883558
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2014 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

NCT01451398
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Technosphere® Insulin, Technosphere Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
50
States / cities
Anaheim, California • Huntington Beach, California • Laguna Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 2 Interventional

Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes

NCT01662921
View directory record Official record
Conditions
Diabetes During Pregnancy
Interventions
NPH, Insulin LISPRO, Insulin glulisine
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

NCT00332488
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Technosphere Insulin, Metformin & Secretagogues, Technosphere Insulin & Metformin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Sep 29, 2026, 2:14 PM EDT
Not listed No phase listed Observational

Salivary Transcriptome Biomarkers for Early Diabetes Detection

NCT02673762
View directory record Official record
Conditions
Pre-diabetes, Type II Diabetes, Insulin Resistance
Interventions
Not listed
Lead sponsor
PeriRx
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Sep 29, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

Feasibility Study of Finesse for Bolus Prandial Insulin Dosing Compared to Multiple Daily Injections

NCT01073566
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Finesse, Pen/Syringe (Usual injection device)
Device
Lead sponsor
Calibra Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 29, 2026, 2:14 PM EDT